A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SAMSON-II; Samson2
- Sponsors Prestige BioPharma
- 21 Nov 2019 Planned End Date changed from 1 Feb 2021 to 1 Jun 2021.
- 21 Nov 2019 Planned primary completion date changed from 1 Nov 2020 to 1 May 2021.
- 21 Nov 2019 Status changed from not yet recruiting to recruiting.